Baseline characteristics	HCQ Group N=33 N(%)	Placebo Group N=30 N(%)	p
Sex male	19 (57,5)	20 (66,6)	0,46
Age (mean; years)	60	59	0,85
Comorbidities Diabetes mellitus Systemic Arterial Hypertension COPD/Asthma Obesity (body mass index > 30)	23 (69,6) 11 (33,3) 14 (42,4) 5 (15,1) 6 (18,1)	24 (80) 13 (43,3) 16 (53,3) 2 (6,6) 11 (36,6)	0,35 0,41 0,39 0,20 0,10
Inclusion criteria Symptoms O2 supplementation Infiltrates on chest CT > 50%	33 (100) 31 (93,9) 15 (45,4)	30 (100) 28 (93,3) 12 (40)	0,12 0,66
Symptoms of acute respiratory infection Axillary temperature (mean, IQR, º C) Oxygen saturation (mean, IQR, %) Respiratory frequency (mean, IQR, bpm)	36,5 (35,5-39,1) 91 (77-99) 21,6 (16-32)	36,7 (35,9-38,6) 92 (84-98) 21 (16-28)	0,40 0,12 0,87
Laboratory measurements Hemoglobin (mean, IQR, g/dL, normal range 12-17) Leucocytes (mean, IQR, x103/µL, normal range 3.9-10.7) Neutrophils (mean, IQR, x103/µL, normal range 1.8-8) Lymphocytes (mean, IQR, x103/µL, normal range 1.2-6) Urea (mean, IQR, mg/dL, normal range 10-40) Creatinine (mean, IQR, mg/dL, normal range 0.5-1.2) AST (mean, IQR, U/L, normal range 6-30) ALT (mean, IQR, U/L, normal range 7-40) Reactive-C-protein (mean, IQR, mg/dL, normal < 0.5) Ferritin (mean, IQR, ng/dL, normal range 4-300) LDH (mean, IQR, U/L, normal range 240-480) Dimer-D (mean, IQR, mcg/mL, normal range <0.5) Troponin (mean, IQR, ng/mL, normal range 0-0.04)	13.6 (10,1-19,3) 7.144 (368-13.600) 4.913 (46-11.433) 1.206 (369-3.394) 37 (19-145) 1.1 (0.5-11.2) 41 (12-124) 48 (9-174) 12.3 (1.6-34) 1.337 (156-9.697) 285 (44-505) 1.4 (0.3-9.6) 0.003 (0.001-0.016)	13.7 (9.4-16.9) 6.669 (638-17.500) 4.686 (81-15.000) 1.156 (300-2.400) 46.1 (17-147) 1.5 (0.5-11.1) 41 (13-98) 32 (5-91) 11.1 (1,2-40) 837 (102-3.449) 301 (142-611) 1.1 (0.19-5.4) 0.01 (0.001-0.09)	0,88 0,55 0,76 0,76 0,20 0,39 0,97 0,04 0,59 0,43 0,56 0,91 0,03

Table 1: Baseline characteristics of the patients by group

COPD = chronic obstructive pulmonary disease; CT = computed tomography; AST = aspartate aminotransferase; ALT = alanine aminotransferase; LDH = lactic dehydrogenase; IQR = interquartile range; bpm = breath per minute

Outcome	HCQ Group N=33 N(%)	Placebo Group N=30 N(%)	p
Mechanical ventilation Time to IOT (mean, days, IQR)	8 (24,2) 4 (1-7)	6 (20) 3 (1-8)	0,68 0,69
Death Time to death (mean, days, IQR)	4 (12,1) 14.5 (6-21)	2 (6,6) 26 (7-45)	0,46 0,51
Adverse events
Increase in hepatic transaminases	1 (3)	0 (0)	0,34
QTc interval prolongation	0 (0)	0 (0)

Corrected QT interval (mean, ms)	D0	D3	D5
HCQ (N=33)	396	406	402
Placebo (N=30)	382	386	398

Tables at a glance

Figures at a glance